Nectar Lifesciences Valuation
Is NECLIFE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NECLIFE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NECLIFE (₹35.26) is trading below our estimate of fair value (₹184.48)
Significantly Below Fair Value: NECLIFE is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NECLIFE?
Key metric: As NECLIFE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is NECLIFE's PE Ratio? | |
|---|---|
| PE Ratio | 128.7x |
| Earnings | ₹61.44m |
| Market Cap | ₹7.91b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | 8.9x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does NECLIFE's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 35.8x | ||
524212 Wanbury | 14.4x | n/a | ₹7.5b |
524075 Albert David | 11.1x | n/a | ₹7.6b |
INDSWFTLAB Ind-Swift Laboratories | 1.7x | n/a | ₹6.3b |
506414 Fermenta Biotech | 116.1x | n/a | ₹9.8b |
NECLIFE Nectar Lifesciences | 128.7x | n/a | ₹7.9b |
Price-To-Earnings vs Peers: NECLIFE is expensive based on its Price-To-Earnings Ratio (128.7x) compared to the peer average (35.8x).
Price to Earnings Ratio vs Industry
How does NECLIFE's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 1.7x | n/a | US$74.22m |
524652 Ind-Swift | 2.8x | n/a | US$13.24m |
| 2 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: NECLIFE is expensive based on its Price-To-Earnings Ratio (128.7x) compared to the Indian Pharmaceuticals industry average (32.7x).
Price to Earnings Ratio vs Fair Ratio
What is NECLIFE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 128.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NECLIFE's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
IOL Chemicals and Pharmaceuticals
₹21.8b
Manufactures and sells pharmaceutical and chemical products in India and internationally.
IOLCP
₹371.55
7D
-6.7%
1Y
-12.4%
Mercury Laboratories
₹1.1b
Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.
538964
₹944.45
7D
-3.5%
1Y
18.1%
Solara Active Pharma Sciences
₹36.4b
Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.
SOLARAPP
₹468.50
7D
-5.7%
1Y
n/a